Tesamorelin — Buy in Canada

What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that is FDA-approved under the brand name Egrifta for the treatment of HIV-associated lipodystrophy. It stimulates the anterior pituitary to produce and release growth hormone by binding to GHRH receptors, resulting in elevated GH and IGF-1 levels and, in clinical studies, significant reductions in visceral adipose tissue. Tesamorelin has a transglutaminase modification at the N-terminus that extends its half-life compared to native GHRH.

VELTRIDE supplies Tesamorelin 2mg lyophilized powder at ≥98% HPLC-verified purity with Certificate of Analysis, shipped discreetly across Canada from West Kelowna, BC. As a clinically validated GHRH analogue, Tesamorelin is among the most credible peptides available for GH axis and metabolic research in Canada.

Research Highlights

• FDA-approved (Egrifta) — robust clinical safety and efficacy data available
• Significant visceral adipose tissue reduction in clinical and research models
• Elevates GH and IGF-1 — well-characterized GHRH receptor agonism
• Studied for cognitive benefits — IGF-1 elevation and hippocampal function
• Improves lipid profiles — triglycerides and HDL improvements in clinical data
• Potential applications in age-related GH decline and metabolic syndrome research
• Pairs synergistically with GHRPs like Ipamorelin for GH pulse amplification

Tesamorelin vs CJC-1295

Tesamorelin has FDA clinical validation that CJC-1295 DAC lacks, making it valuable for research requiring clinical reference data. CJC-1295 has a longer half-life due to DAC modification. Both pair well with GHRPs like Ipamorelin for amplified GH pulse research.

Related Products